(AQST) Aquestive Therapeutics - Ratings and Ratios

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a biopharmaceutical company specializing in the development and commercialization of innovative pharmaceutical products. The company focuses on addressing unmet medical needs through its proprietary PharmFilm® technology, which enables the delivery of medications via soluble films. This technology enhances bioavailability, improves patient compliance, and offers a more convenient alternative to traditional oral medications.

The companys commercial portfolio includes Sympazan® (clobazam), an oral soluble film for the treatment of seizures associated with Lennox-Gastaut syndrome; Suboxone®, a sublingual film formulation of buprenorphine and naloxone for opioid dependence; and Zuplenz®, an oral soluble film formulation of ondansetron for chemotherapy-induced nausea and vomiting. Additionally, Aquestive markets Azstarys®, a once-daily treatment for attention deficit hyperactivity disorder (ADHD).

Aquestives pipeline includes Libervant™, a buccal soluble film formulation of diazepam for acute repetitive seizures; KYNMOBI™, a sublingual film formulation of apomorphine for Parkinsons disease; and Exservan™, an oral soluble film formulation of riluzole for amyotrophic lateral sclerosis (ALS). The company is also advancing AQST-108, a sublingual film formulation of systemic epinephrine for non-anaphylaxis conditions, and Anaphylaxis, an epinephrine sublingual film for allergic reactions. Its Adrenaverse™ platform focuses on epinephrine delivery for emergency allergic reactions.

From a technical perspective, AQST is trading at $2.80 with a 20-day moving average of $3.02, indicating recent price weakness. The 50-day and 200-day moving averages are $3.21 and $3.80, respectively, suggesting downside resistance. The average true range (ATR) of 0.19 reflects moderate volatility. On the fundamental side, the company has a market cap of $254.8 million, a price-to-sales ratio of 4.33, and a return on equity (RoE) of 77.48, highlighting strong operational efficiency despite a lack of profitability.

Three-Month Forecast: Based on the technical and fundamental data, AQST is expected to face resistance at the 50-day and 200-day moving averages, potentially capping upside momentum. The stock may oscillate between $2.60 and $3.20 over the next three months, with volatility driven by ATR. Fundamental strength in revenue generation could support the stock, but profitability concerns may limit upside. Investors should monitor pipeline advancements and commercial execution for potential catalysts.

Aquestive Therapeutics is headquartered in Warren, New Jersey, and was incorporated in 2004. For more information, visit https://www.aquestive.com.